- Futura Medical
- 19 September 2025 13:01:13
Source: Sharecast
The AIM-listed consumer healthcare firm, which is behind erectile dysfunction treatment Eroxon, said in-market sales of the latter have been slower than originally expected.
This trend has continued across all markets, it said, most notably in the USA where the market size and potential is considered to be the greatest.
As a result, initial inventory orders from its distributors, recognised by Futura in 2024, continue to meet current-year demand meaning that replenishment sales from Futura remain significantly below forecast.
In addition, the company said that under the terms of its agreement with Haleon, a $2.5m payment is due upon the granting of a US patent for Eroxon that meets the contractual definition of a valid patent claim.
All filings have been made and it had been expected that this milestone would be achieved in FY 2025, with the payment forming a portion of overall revenue in FY 2025. However, the company said it’s now expected to crystalise in the first half of 2026.
"As a result of slower sales across all markets and with the US patent milestone payment now expected to fall due in H1 2026, the company expects revenues for FY 2025 to be materially below expectations," it said.
Revenue for FY 2025 is now expected to be between £1.3m and £1.4m. This compares to market expectations for revenue of £5m and a loss after tax of £3.5m.
At 1245 BST, the shares were down 50% at 4.40p.
